BioAtla. has filed a patent for a method to prepare a conditionally active polypeptide by evolving a DNA encoding the parent polypeptide. The patent also covers pharmaceutical compositions, nanoparticle and drug conjugates, and various uses of the conditionally active polypeptide. GlobalData’s report on BioAtla gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioAtla, Personalized cancer vaccines was a key innovation area identified from patents. BioAtla's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Method of preparing conditionally active polypeptide from parent polypeptide
A recently filed patent (Publication Number: US20230374702A1) discloses a method for preparing a conditionally active antibody or antibody fragment from a parent antibody, single-chain antibody, or antibody fragment. The method involves evolving the DNA encoding the parent antibody to increase the number of Aspartic acid residues, Glutamic acid residues, or both, creating mutant DNAs. These mutant antibodies or fragments are then expressed and the conditionally active antibody is selected based on its reversible decrease in activity at pH 6.0 compared to pH 7.4, with a ratio of at least 1.3:1.
The evolving step in the method employs site-directed mutagenesis techniques such as oligonucleotide-mediated mutagenesis, PCR mutagenesis, or cassette mutagenesis. By introducing acidic amino acid codons into the DNA encoding the parent antibody, the method aims to modify the activity of the resulting antibody or fragment. The assays are performed in solutions containing proteins found in blood, such as albumin, and exclude serum. Additionally, the method allows for the selection of the conditionally active antibody based on properties like affinity, expression level, and humanization, with the ratio of activity at pH 6.0 to pH 7.4 ranging from 1.7:1 to as high as 8.0:1. This innovative approach could have significant implications in the development of antibodies with tailored activity profiles for various applications.
To know more about GlobalData’s detailed insights on BioAtla, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
